The pharmacokinetics of a single 500-mg intramuscular dose of ceftizoxime were studied in 11 healthy adult volunteers and in 22 patients with various degrees of renal dysfunction. The mean serum half-life of ceftizoxime was 1.44 h in normal subjects and 30.2 h in hemodialysis patients. A significant correlation (P < 0.001) between the elimination rate constant of ceftizoxime and creatinine clearance was demonstrated. The mean urinary recovery in normal subjects was 75.6% within 6 h of dosage; recovery decreased progressively with reduced renal function.
Ceftizoxime, a new parenteral cephalosporin, is more active in vitro against various gramnegative bacilli, including opportunistic pathogens such as Enterobacter spp., Citrobacter spp., and Serratia marcescens, than are older cephalosporins (6, 7, 8, 14) . Ceftizoxime has a level of therapeutic effectiveness comparable to that of cefotaxime against various experimental infections (8).
Since ceftizoxime is excreted mainly via the kidneys (13) , its disposition in subjects with impaired renal function is of some concern. This study was designed to compare the pharmacokinetics of this cephalosporin in subjects with normal renal function and patients with various degrees of renal dysfunction.
MATERIALS AND METHODS
A total of 11 healthy male volunteers and 22 patients with various degrees of renal dysfunction were studied. Informed consent was obtained from all participants before the study. The mean age was 50.3 years (range, 20 to 78 years), and the mean weight was 56.0 kg (range, 32 to 72 kg). Endogenous creatinine clearance corrected for 1.73 m2 of body surface area was used as an indicator of renal function. The 33 subjects were divided into five groups according to the severity of renal dysfunction as follows: group 1, 11 male healthy volunteers with creatinine clearances of 100.6 to 159.2 ml/min; group 2, 10 patients with creatinine clearances of 60.9 to 94.6 ml/min; group 3, 5 patients with creatinine clearances of 30.4 to 47.5 ml/min; group 4, 4 patients with creatinine clearances of 6.8 to 13.4 ml/min; and group 5, 3 hemodialysis patients with creatinine clearances of 0 to 1.2 ml/min. The patients in group 5 were examined between hemodialysis sessions.
All subjects were given a single intramuscular (i.m.) injection into a gluteal region of 500 mg of ceftizoxime dissolved in 2 ml of distilled water. Blood samples were obtained before injection and at 0.5, 1, 2, 4, and 6 h after injection in all subjects and additionally at 24 h in patients whose creatinine clearance was below 30 ml/min. Urine specimens were collected during 0 to 2, 2 to 4, and 4 to 6 h after administration in 30 of the 33 subjects.
Serum and urine samples were stored at -20°C until assay. Concentrations of ceftizoxime in serum and urine were determined by the disk-plate diffusion method with Bacillus subtilis ATCC 6633 as the test organism and sodium citrate agar (1.0%1 sodium citrate-1.0% agar-0.5% polypeptone-0.3% beef extract) as the test medium. Plates were incubated at 37°C for 18 to 20 h, and inhibition zones were measured and compared with similarly prepared standards. These assays were performed in triplicate. Standard solutions for the measurement of ceftizoxime concentrations in serum and urine were prepared in pooled normal human sera and 0.067 M phosphate buffer (pH 7.0), respectively (12) . Ceftizoxime was supplied by Fujisawa Pharmaceutical Co., Ltd. Pharmacokinetic parameters based on a one-compartment open model were calculated by the NONLIN nonlinear regression program (11) .
RESULTS
Serum concentrations. Table 1 shows the mean serum concentrations of ceftizoxime in each group. The mean peak serum concentrations were attained at 0.5 to 1 h in groups 1 through 4 and at 2 h in group 5 and tended to be higher in patients with impaired renal function. There was a significant negative correlation (P < 0.01) between peak serum concentration and creatinine clearance.
Urinary excretion. Pharmacokinetic analysis. The pharmacokinetic parameters of ceftizoxime in each group are summarized in Table 3 . There was no significant correlation between the absorption rate constant of ceftizoxime and creatinine clearance. However, the mean absorption rate constants in groups 3, 4, and 5 tended to be lower than in groups 1 and 2.
A significant correlation (P < 0.001) was obtained when the individual elimination rate constant (k,l) was plotted against creatinine clearance ( Fig. 1) , resulting in the equation y = 0.0186 + 0.00414x, where y and x represent ket and creatinine clearance, respectively. Plotting the individual serum half-life (t1/2) against creatinine clearance gave a hyperbolic curve. The t1/2 of ceftizoxime was 1.44 h in healthy volunteers but was prolonged to 30.2 h in hemodialysis patients. The theoretical t1/2 in normal subjects, calculated by using the regression line described above and the equation t1/2 = ln 2Ike,, was 1.60 h when the lower limit of normal creatinine clearance was set at 100 ml/min.
The mean apparent volume of distribution in normal subjects was 22.6 liters or 35.4% (liters per kilogram of body weight). There was no significant relationship between the apparent volume of distribution and creatinine clearance. Body and renal clearances were corrected for 1.73 m2 of body surface area. The mean body clearance and renal clearance in normal subjects were 178.7 and 135.1 ml/min, respectively. The results demonstrated significant correlations between the body clearance and creatinine clearance (P < 0.001), between the renal clearance and creatinine clearance (P < 0.001) (Fig. 2) , and between the body clearance and renal clearance (P < 0.001). The regression line correlating the renal clearance and creatinine clearance values, encompassing renal failure patients as well as normal subjects, had a slope of 1.15. The relationship between the area under the serum concentration curve and creatinine clearance was hyperbolic.
DISCUSSION
In the present study, we determined the serum and urinary concentrations of ceftizoxime after a single 500-mg i.m. injection of the drug into 33 subjects with various degrees of renal function. The serum ceftizoxime concentrations increased as renal function declined, with the mean peak serum concentration in hemodialysis patients being 2.8 times that of normal subjects, due to slower renal excretion in patients with renal insufficiency. The mean t1/2 of ceftizoxime in normal subjects was 1.44 h, and the theoretical t1/2 was calculated to be 1.60 h on the basis of the linear correlation between the kei of ceftizoxime and creatinine clearance. These values are slightly lower than those previously reported for ceftizoxime (13) . The t1,2 of ceftizoxime was prolonged in patients with impaired renal function. Both the t1/2 and the area under the serum concentration curve of ceftizoxime increased as renal function decreased, but only a slight increase was noted in patients with moderate renal impairment. The mean apparent volume of distribution of ceftizoxime in normal subjects was 35.4% of body weight, compared with 12.2% for Our pharmacokinetic study showed a slight difference between patients with creatinine clearance of more than 30 ml/min and normal subjects. Compared with other cephalosporins, ceftizoxime had a relatively long t1,2 similar to those of cefazolin, cefoperazone, and moxalactam in normal subjects (1, 2, 13, 15) . The drug accumulated as do cefazolin and moxalactam (to a greater degree than cefamandole, cefoxitin, and cefotaxime) in patients with renal insufficiency (2, 4, 5, 9, 10) . Although there is no report concerning renal, hepatic, or hematological toxicity, dosage adjustment might be necessary in patients with severe renal dysfunction to avoid excessive serum levels. For example, the method of Dettli (3) may be appropriate for indicating the necessity for dose reduction, prolongation of the dosage interval, or both.
